Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir

Journal of Pediatric Gastroenterology and Nutrition

Volumn 67, Issue 5, 2018, Pages 626-630

  El Karaksy, Hanaa ^a   Mogahed, Engy Adel ^a   Abdullatif, Hala ^a   Ghobrial, Carolyne ^a   El Raziky, Mona S ^a   El Koofy, Nehal ^a   El Shabrawi, Mortada ^a   Ghita, Haytham ^a   Baroudy, Sherif ^a   Okasha, Sawsan ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Adolescents; Children; Hepatitis C virus; Ledipasvir; Sofosbuvir; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; SERUM ALBUMIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; IRRITABILITY; JAUNDICE; MALE; NAUSEA; NIGHTMARE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RISK ASSESSMENT; SIDE EFFECT; SLEEP WALKING; SUSTAINED VIROLOGIC RESPONSE; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; VIRUS LOAD; CHILD; DRUG EFFECT; EGYPT; GENETICS; GENOTYPE; HEPACIVIRUS; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHILD; EGYPT; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; SUSTAINED VIROLOGIC RESPONSE; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 85055614009     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000002101     Document Type: Article

References (33)

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
2. FDA News Release. FDA approves two hepatitis C drugs for pediatric patients. FDA. Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm551407.htm. Published April 7, 2017. Accessed February 20, 2018.
3. El-Zanaty and Associates [Egypt], and ICF International. Egypt Health Issues Survey 2015. Cairo, Egypt, and Rockville, MD: Ministry of Health and Population and ICF International; 2015.
4. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
5. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8.
6. Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and metaanalysis. Clin Infect Dis 2013;56:961-7.
7. El-Karaksy HM, Mogahed EA, El-Raziky MS, et al. Safety and efficacy of combined treatment with pegylated interferon alpha-2b and ribavirin for HCV genotype 4 in children. J Interferon Cytokine Res 2016;36:1-8.
8. Schwarz KB, Molleston JP, Jonas MM, et al. Durability of response in children treated with pegylated interferon alfa-2a ± ribavirin for chronic hepatitis C. J Pediatr Gastroenterol Nutr 2016;62:93-6.
9. Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, et al. Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C genotype 1: a systematic review and network metaanalysis. PLoS One 2015;10:e0145953.
10. Indolfi G, Serranti D, Resti M. Direct-acting antivirals for children and adolescents with chronic hepatitis C. Lancet Child Adolesc Health 2018;2:298-304.
11. Indolfi G, Thorne C, El Sayed MH, et al. The challenge of treating children with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2017;64:851-4.
12. Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr 2016;28:93-100.
13. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-8.
14. El-Khayat HR, Kamal EM, El-Sayed MH, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther 2018;47:838-44.
15. Abdel-Hamid M, El-Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007;88:1526-31.
16. AASLD, 2018. https://www.hcvguidelines.org/unique-populations/chil-dren. Last update: May 24, 2018. Accessed June 2018.
17. Indolfi G, Hierro L, Dezsofi A, et al. Treatment of chronic hepatitis c virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:505-15.
18. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199-236.
19. Schwartz GJ, Brion LP, Spitzer A. Proportionality constant for calculating GFR. Pediatr Clin North Am 1987;34:571.
20. Shiha G, Esmat G, Hassany M, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2018[Epub ahead of print].
21. Wirth S, Rosenthal P, Gonzalez-Peralta R, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-10.
22. El-Shabrawi MH, Abdo AM, El-Khayat HR, et al. Shortened 8 weeks course of dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018;66: 425-7.
23. Yakoot M, El-Shabrawi MH, AbdElgawad MM, et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018;67:86-9.
24. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012;18:99-104.
25. El Sherbini A, Mostafa S, Ali E. Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Aliment Pharmacol Ther 2015;42:12-9.
26. Kirby B. Adult doses of sofosbuvir plus ribavirin or ledipasvir/sofos-buvir provided comparable plasma exposures and tolerable safety profile in adolescents with hepatitis C virus (HCV) infection. Presented at: American Association for the Study of Liver Disease Annual Meeting; 2015; San Francisco, CA.
27. American Association for the Study of Liver Diseases (AASLD). 2016. Recommendations for Testing, Managing and Treating Hepatitis C. Available at: http://hcvguidelines.org. Accessed November 2017.
28. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66:153-94.
29. Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702-26.
30. Kondili LA, Gaeta GB, Brunetto MR, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One 2017;12:e0185728.
31. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598-609.
32. Cox AL. Global control of hepatitis C virus. Science 2015;349:790-1.
33. Pawlotsky JM, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62:87-99.